惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Martin Fowler
Martin Fowler
博客园 - 三生石上(FineUI控件)
WordPress大学
WordPress大学
博客园_首页
宝玉的分享
宝玉的分享
S
SegmentFault 最新的问题
Jina AI
Jina AI
Hugging Face - Blog
Hugging Face - Blog
V
Visual Studio Blog
美团技术团队
IT之家
IT之家
罗磊的独立博客
Blog — PlanetScale
Blog — PlanetScale
Google DeepMind News
Google DeepMind News
月光博客
月光博客
Microsoft Azure Blog
Microsoft Azure Blog
H
Help Net Security
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
Last Week in AI
Last Week in AI
博客园 - 叶小钗
M
MIT News - Artificial intelligence
B
Blog RSS Feed
有赞技术团队
有赞技术团队
Y
Y Combinator Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings C...
SA Transcripts · 2026-05-08 · via All Articles on Seeking Alpha

Q1: 2026-05-07 Earnings Summary

EPS of $0.42 misses by $0.29

 | 

Revenue of

$171.17M

(0.38% Y/Y)

misses by $2.22M

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call May 7, 2026 5:00 PM EDT

Company Participants

Dan Dischner - Senior Vice President of Human Resources & Corporate Communication
William Peters - CFO, Executive VP of Finance, Treasurer & Director
Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations

Conference Call Participants

Serge Belanger - Needham & Company, LLC, Research Division
Anthea Li - Jefferies LLC, Research Division
Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division
Naoki Martin - Piper Sandler & Co., Research Division

Presentation

Operator

Greetings, and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in the press release issued today and in the presentation on the company's website.

Also, please refer to our SEC filings, which can be found on our company's website and the SEC's website for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliations to U.S. GAAP may be found in our earnings release. Please note, this conference is being recorded. Our speakers today are Mr. Bill Peters, CFO; Mr. Dan Dischner, Senior Vice President of Corporate Communications; and Mr. Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations.

I will now turn the conference over to your host, Mr. Dan Dischner, Senior Vice President of Corporate Communications. Dan, you may begin.

Dan Dischner
Senior Vice President of Human Resources & Corporate Communication

Thank you, Paul. Good afternoon, everyone, and thank